The immune based investigation delineated the immune characteristics of DC, and disclosed the potential actions of anti-CD248 in the Cold tumor cluster, and anti-CD276 or CAR-T/CD276 in the Hot tumor cluster, providing a clinic direction for DC. This evidence concerns the gene CD248 and neoplasm.